Filing Details

Accession Number:
0001209191-14-026493
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-04-08 18:41:03
Reporting Period:
2014-04-07
Filing Date:
2014-04-08
Accepted Time:
2014-04-08 18:41:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1571498 Epizyme Inc. EPZM Pharmaceutical Preparations (2834) 261349956
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1577034 J Robert Gould C/O Epizyme, Inc.
400 Technology Square
Cambridge MA 02139
Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Acquisiton 2014-04-07 30,000 $0.51 30,000 No 4 M Direct
Common Stock, Par Value $0.0001 Per Share Disposition 2014-04-07 30,000 $20.22 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-04-07 30,000 $0.00 30,000 $0.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
777,223 2020-03-17 No 4 M Direct
Footnotes
  1. The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2013.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 per share to $20.8299 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. This option was granted on March 18, 2010 with respect to 870,557 shares of Common Stock, with 25% vesting on March 18, 2011 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.